FilingsTodaySam-A Pharm.
At a glance
Sam-A Pharm. filed 15 disclosures in the last 12 months.
Revenue for 2025 was ₩77.8B, down 18.6% on 2024. Operating margin was 14.1% against 25.6% a year earlier. Debt was 8% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩36.4B and operating profit of ₩4B.
The 2025 annual report lists 310 employees with an average tenure of 8.6 years and average pay of ₩56M, #1174 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩140M each on average. It paid ₩850 per common share in cash dividends, against ₩800 a year earlier (+6.3%). 허 준 and related parties held 65.58% at year end.
From the 2025 annual report
Staff: 310 (238 men, 72 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩17.3B. Directors and auditors: 5, paid ₩698M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩850 | ₩800 | ₩750 |
| Payout ratio | 40.1% | 22.1% | 21.4% |
| Yield (as filed) | 5.20% | 4.70% | 4.50% |
| Total cash dividends | ₩5.2B | ₩4.9B | ₩4.6B |
Largest shareholder
허 준 holds 47.65%; with 2 related parties the group holds 65.58% of common shares at year end.
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
No key filings in the last 12 months.
Other filings
Links open the original filing on DART, in Korean.